trending Market Intelligence /marketintelligence/en/news-insights/trending/EYOomvBnGsq6DYG4_ujIng2 content esgSubNav
In This List

Marksans secures US approval to market generic benign prostatic hyperplasia drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Marksans secures US approval to market generic benign prostatic hyperplasia drug

Marksans Pharma Ltd. secured U.S. FDA approval to market a generic version of GlaxoSmithKline PLC's Avodart for the treatment of benign prostatic hyperplasia, or BPH.

BPH is an age-associated prostate gland enlargement that can cause urination difficulty. The Indian pharmaceutical said it will launch dutasteride soft gelatin capsules in dosages of 0.5 milligrams immediately.

Elsewhere, the company noted that the U.S. FDA recorded four violations during an inspection of its manufacturing facility in Goa, India.

Marksans said it had already started addressing the issues.